The document outlines a green belt project aimed at improving the success rate of SPL submissions from 54.62% to 95% by December 2011, addressing issues with frequent failures at FDA ESG. It includes a detailed analysis of the process capability before and after implementation, showing a significant reduction in defects from 54 to 2, leading to enhanced customer satisfaction and reduced turnaround time. Key milestones and a proposed control plan are also described to ensure ongoing improvements.